Lineage Cell Therapeutics (LCTX) Profit After Tax (2010 - 2026)
Lineage Cell Therapeutics (LCTX) reported Profit After Tax of -$4.8 million for Q1 2026, down 16.15% on a YoY basis from -$5.7 million in Q1 2025, and down 665.45% quarter-over-quarter from $851000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Profit After Tax (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics has reported Profit After Tax for 17 years, with the latest figure at -$4.8 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax fell 16.15% year-over-year to -$4.8 million; the trailing twelve-month figure through Mar 2026 stood at -$64.2 million (down 296.48% YoY), and the FY2025 full-year result was -$63.5 million, down 241.41% from the prior year.
- Profit After Tax for Q1 2026 stood at -$4.8 million, down from $851000.0 in the prior quarter.
- The five-year high for Profit After Tax was $851000.0 in Q4 2025, with the low at -$30.5 million in Q2 2025.
- Historically, Profit After Tax has averaged -$7.9 million across 5 years, with a median of -$5.8 million in 2024.
- The largest YoY upside for Profit After Tax was 125.97% in 2025 against a maximum downside of 892.37% in 2025.
- Lineage Cell Therapeutics' Profit After Tax stood at -$6.4 million in 2022, then grew by 24.85% to -$4.8 million in 2023, then jumped by 31.37% to -$3.3 million in 2024, then soared by 125.97% to $851000.0 in 2025, then sank by 665.45% to -$4.8 million in 2026.
- The last three Profit After Tax figures came in at -$4.8 million (Q1 2026), $851000.0 (Q4 2025), and -$29.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn | -4.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.81 Mn |
| Dec 31, 2025 | 851,000.00 |
| Sep 30, 2025 | -29.78 Mn |
| Jun 30, 2025 | -30.46 Mn |
| Mar 31, 2025 | -4.14 Mn |
| Dec 31, 2024 | -3.28 Mn |
| Sep 30, 2024 | -3.00 Mn |
| Jun 30, 2024 | -5.77 Mn |
| Mar 31, 2024 | -6.54 Mn |
| Dec 31, 2023 | -4.78 Mn |
| Sep 30, 2023 | -7.11 Mn |
| Jun 30, 2023 | -5.20 Mn |
| Mar 31, 2023 | -4.40 Mn |
| Dec 31, 2022 | -6.35 Mn |
| Sep 30, 2022 | -6.07 Mn |
| Jun 30, 2022 | -6.76 Mn |
| Mar 31, 2022 | -7.09 Mn |
| Dec 31, 2021 | -28.99 Mn |
| Sep 30, 2021 | -7.82 Mn |
| Jun 30, 2021 | -4.79 Mn |